ProCE Banner Activity

Therapeutic Strategies for Pretreated Metastatic UC: A Nursing Perspective

Multimedia
Review important nursing considerations and tips for educating patients undergoing treatment with erdafitinib or enfortumab vedotin for advanced urothelial carcinoma.

Released: November 30, 2020

Expiration: November 29, 2021

No longer available for credit.

Share

Faculty

Susan Roethke

Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Nurse Practitioner
Department of Hematology/Oncology
Genitourinary Medical Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Astellas Seattle Genetics

Janssen administered by Scientific Affairs

Learning Objectives

  • Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
  • Describe to patients and colleagues the available data and unique mechanisms of action of novel targeted therapies for the treatment of advanced urothelial carcinoma
  • Evaluate the toxicity profile as well as the pharmacokinetics and exposure-response association of approved antibody–drug conjugates in urothelial carcinoma

Faculty Disclosure

Primary Author

Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Nurse Practitioner
Department of Hematology/Oncology
Genitourinary Medical Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Susan Roethke, CRNP, MSN, AOCNP, ANP-BC, has disclosed that she has received fees for non-CME/CE services from Astellas and Pfizer.

Staff Disclosure

Staff

Megan Capel,

Design Lead

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that his spouse/partner has received salary from AstraZeneca and has ownership interest in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.